SynapseNovember 1, 2025Oliver H Miller, Nils Grabole, Isabelle Wells et al.
Low-dose ketamine is an efficacious antidepressant for treatment-resistant unipolar and bipolar depressed patients. Major depressive disorder patients receiving a single infusion report elevated mood within 2 h, and ketamine's antidepressant effects have been observed as long as 7 days posttreatment. In light of this remarkable observation, efforts have been undertaken to "reverse-translate"...
Translational PsychiatryOctober 31, 2025Kristin L Dawson, Athena May Jean M. Carangan, Jessica Klunder et al.2 citations
Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine's effects on...
Background. The water soluble form of quercetin, corvitin, may potentially be useful for preventing complications of short-term ketamine analgesia in children and adults, as well as preventing myocardial damage in the treatment of depression and post- traumatic stress disorder. Purpose – was to determine the effect of quercetin on the myocardium of rats under conditions of ketamine-induced...
Background: Treatment-resistant depression (TRD) affects up to a third of patients with major depressive disorder and remains difficult to manage with conventional therapies. Rapid-acting antidepressants targeting the glutamatergic system, such as ketamine, esketamine, and dextromethorphan-bupropion, have emerged as promising alternatives. Nitrous oxide, also an NMDA receptor antagonist, has...
BACKGROUND: Over the past ten years, several psychedelic compounds, including tryptamines like lysergic acid diethylamide/LSD, psilocybin, ayahuasca, and dimethyltryptamine/DMT, have been tested in clinical trials for a range of psychiatric conditions, such as anxiety and depression. While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are...
INTRODUCTION: Functional impairment is commonly reported amongst individuals with major depressive disorder (MDD) or treatment-resistant depression (TRD). Extant evidence suggests that ketamine and esketamine, N-methyl-D-aspartate (NMDA) receptor antagonists and glutamatergic modulators, have shown efficacy in treating MDD/TRD. While symptom reduction remains central to treatment, many...
Background: Comorbid depressive symptoms are prevalent in patients with breast cancer, which adversely impacts postoperative recovery outcomes. Esketamine has emerged as a promising intervention for perioperative depression due to its rapid and sustained effects. This study aims to investigate the impact of the continuous intravenous infusion of esketamine during the perioperative period on...
Background Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relative safety remains unclear. This review aims to update the evidence on the safety of two agents for MDD and indirectly compare their safety and tolerability. Method We systematically searched PubMed, PsycINFO, Embase, and Cochrane databases up to 1 May...
There has been a renewed interest in the use of various psychedelic agents as potential therapies for multiple psychiatric conditions, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), to name a few. This follows the recent accumulation of evidence for ketamine pharmacotherapy and a rapid proliferation of clinics/programs...
Ketamine, a noncompetitive N-methyl-D-aspartate receptor antagonist, is associated with chronic abuse leading to schizophrenia-like cognitive deficits. The gut-brain axis may play a role in mediating substance-induced neurotoxicity; however, its involvement in ketamine-induced cognitive impairment remains poorly understood. Here, chronic ketamine exposure was administered intraperitoneally to...